Related references
Note: Only part of the references are listed.Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistance
Lin Liu et al.
AIDS (2008)
Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006
Patrick A. Coffie et al.
CLINICAL INFECTIOUS DISEASES (2008)
Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination Antiretroviral therapy containing tenofovir
Viktor von Wyl et al.
CLINICAL INFECTIOUS DISEASES (2008)
Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects
Daniel R. Kuritzkes et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection
Susan J. Little et al.
JOURNAL OF VIROLOGY (2008)
Broad Antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137)
Kazuya Shimura et al.
JOURNAL OF VIROLOGY (2008)
Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial
Benjamin H. Chi et al.
LANCET (2007)
Rapid and durable Antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection - Results of a 48-week controlled study
Martin Markowitz et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2007)
Predictors of long-term viral failure among Ugandan children and adults treated with antiretroviral therapy
Moses R. Kamya et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2007)
Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1:: a meta-analysis
Elise Arrive et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2007)
Emergence of HIV-1 drug resistance in previously untreated patients initiating combination Antiretroviral treatment -: A comparison of different regimen types
Viktor Von Wyl et al.
ARCHIVES OF INTERNAL MEDICINE (2007)
HIV-1 antiretroviral drug resistance in recently infected patients in Abidjan, Cote d'Ivoire: A 4-year survey, 2002-2006
Thomas D'Aquin Toni et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2007)
Predictive genotypic algorithm for virologic response to lopinavir-ritonavir in protease inhibitor-experienced patients
Martin S. King et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3′-azido-3′-dideoxythymidine
Jessica H. Brehm et al.
JOURNAL OF VIROLOGY (2007)
Long-term persistence of transmitted HIV drug resistance in male genital tract secretions: Implications for secondary transmission
Davey M. Smith et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment experienced patients: AIDS clinical trials group 5211
Roy M. Gulick et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial
Adriano Lazzarin et al.
LANCET (2007)
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial
Jose Valdez Madruga et al.
LANCET (2007)
Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3-Azido-3'-deoxythymidine resistance
Krista A. Delviks-Frankenberry et al.
JOURNAL OF VIROLOGY (2007)
Changing rates and patterns of drug resistance mutations in antiretroviral-experienced HIV-infected patients
Carmen De Mendoza et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2007)
Transmission of multidrug-resistant HIV-1:: 5 years of immunological and virological survey
Constance Delaugerre et al.
AIDS (2007)
Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection
Clare L. Booth et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry
Pavel Pugach et al.
VIROLOGY (2007)
Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients
Isabelle Pellegrin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry
Mike Westby et al.
JOURNAL OF VIROLOGY (2007)
Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism
Jeannette M. Whitcomb et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails
Somnuek Sungkanuparph et al.
CLINICAL INFECTIOUS DISEASES (2007)
The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients
Anne Maillard et al.
JOURNAL OF CLINICAL VIROLOGY (2007)
Prevalence of primary genotypic resistance in a UK centre: comparison of primary HIV-1 and newly diagnosed treatment-naive individuals
Julie Fox et al.
AIDS (2007)
Response to antiretroviral therapy after a single, peripartum dose of nevirapine
Shahin Lockman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Food and drug administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients
Lisa K. Naeger et al.
AIDS (2007)
Mutations in the connection domain of HIV-1 reverse transcriptase increase 3′-azido-3′-deoxythymidine resistance
Galina N. Nikolenko et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals
Martin Markowitz et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2006)
High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens
Florence Doualla-Bell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance
Hong-Ha M. Truong et al.
AIDS (2006)
Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir
John D. Baxter et al.
JOURNAL OF VIROLOGY (2006)
Once-daily abacavir/lamivudine/zidovudine plus tenofovir for the treatment of HIV-1 infection in antiretroviral-naive subjects: A 48-week pilot study
Richard Elion et al.
HIV CLINICAL TRIALS (2006)
Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004
Joris Hemelaar et al.
AIDS (2006)
Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: Results of a clonal analysis
Jing Lu et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2006)
Treatment for adult HIV infection - 2006 recommendations of the International AIDS Society-USA panel
Scott M. Hammer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency
Elias K. Halvas et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2006)
HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture
Bluma G. Brenner et al.
AIDS (2006)
Web resources for HIV type 1 genotypic-resistance test interpretation
TF Liu et al.
CLINICAL INFECTIOUS DISEASES (2006)
Different methods to calculate the inhibitory quotient of boosted single protease inhibitors and their association with virological response
A Winston et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2006)
Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatmentexperienced patients
LK Naeger et al.
AIDS (2006)
Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1 - A decade of experience
A Shet et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2006)
Susceptibility to antiretroviral drugs of CRF01_AE, CRF02_AG, and subtype C viruses from untreated patients of Africa and Asia: Comparative genotypic and phenotypic data
HJ Fleury et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2006)
Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance
D Descamps et al.
JOURNAL OF MEDICAL VIROLOGY (2006)
Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients
S Vora et al.
AIDS (2006)
Algorithms for the interpretation of HIV-1 genotypic drug resistance information
Jurgen Vercauteren et al.
ANTIVIRAL RESEARCH (2006)
Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms -: Data from seroconverters in the CASCADE collaboration from 1987 to 2003
BND Masquelier et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2005)
Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study
P Cane et al.
BMJ-BRITISH MEDICAL JOURNAL (2005)
Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1
JM Strizki et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G
AB Abecasis et al.
AIDS (2005)
Detection of minor populations of drug-resistant HIV-1 in acute seroconverters
KJ Metzner et al.
AIDS (2005)
Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis
PE Sax et al.
CLINICAL INFECTIOUS DISEASES (2005)
A direct comparison of drug susceptibility to HIV type 1 from antiretroviral experienced subjects as assessed by the Antivirogram and PhenoSense assays and by seven resistance algorithms
L Ross et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2005)
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1
G Fätkenheuer et al.
NATURE MEDICINE (2005)
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity
P Dorr et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro
M Mink et al.
JOURNAL OF VIROLOGY (2005)
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe:: Implications for clinical management
AMJ Wensing et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Comparison of HIV type 1 protease inhibitor susceptibility results in viral samples analyzed by phenotypic drug resistance assays and by six resistance algorithms:: An analysis of a subpopulation of the CHORUS cohort
L Ross et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2005)
HIV-1 proteases from drug-naive West African patients are differentially less susceptible to protease inhibitors
M Kinomoto et al.
CLINICAL INFECTIOUS DISEASES (2005)
A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: The resistance and dosage adapted regimens (RADAR) study
C Torti et al.
CLINICAL INFECTIOUS DISEASES (2005)
Drug resistance and antiretroviral drug development
RW Shafer et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Guidelines for the management of chronic kidney disease in HIV-infected patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America
SK Gupta et al.
CLINICAL INFECTIOUS DISEASES (2005)
TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates
S De Meyer et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients
AG Marcelin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Clinically relevant genotype interpretation of resistance to didanosine
AG Marcelin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in anti retroviral-naive chronically infected patients in 2001-2002
D Descamps et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2005)
HIV-1 drug resistance: Degree of underestimation by a cross-sectional versus a longitudinal testing approach
PR Harrigan et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor
C Watson et al.
MOLECULAR PHARMACOLOGY (2005)
Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41
L Xu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis
S Palmer et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2005)
Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20)
J Lu et al.
JOURNAL OF VIROLOGY (2004)
Diagnosis, management, and treatment of hepatitis C
DB Strader et al.
HEPATOLOGY (2004)
Comparison of drug resistance mutations and their interpretation in patients infected with non-B HIV-1 variants and matched patients infected with HIV-1 subtype B
B Montes et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2004)
Synonymous genetic polymorphisms within Brazilian human immunodeficiency virus type 1 subtypes may influence mutational routes to drug resistance
AT Dumans et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors
C Charpentier et al.
JOURNAL OF VIROLOGY (2004)
Surveillance of HIV antiretroviral drug resistance in treated individuals in England: 1998-2000
P Scott et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor
SE Kuhmann et al.
JOURNAL OF VIROLOGY (2004)
Comparative evaluation of three computerized algorithms for prediction of antiretroviral susceptibility from HIV type 1 genotype
M Zazzi et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy
M Wirden et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1
L Myint et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy
M Violin et al.
AIDS (2004)
Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates
PR Sista et al.
AIDS (2004)
Persistence of primary drug resistance among recently HIV-1 infected adults
JD Barbour et al.
AIDS (2004)
Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes
B Ledergerber et al.
LANCET (2004)
The prevalence of antiretroviral drug resistance in the United States
DD Richman et al.
AIDS (2004)
Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients
AG Marcelin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Performance of ViroSeq HIV-1 Genotyping System in routine practice at a Belgian clinical laboratory
B Maes et al.
JOURNAL OF VIROLOGICAL METHODS (2004)
Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viraemia under T-20
AG Marcelin et al.
AIDS (2004)
Prevalence of HIV-1 primary drug resistance in seroconverters of the ICoNA cohort over the period 1996-2001
M Violin et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2004)
Mutation D30N is not preferentially selected by human immunodeficiency virus type I subtype C in the development of resistance to nelfinavir
Z Grossman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France
ML Chaix et al.
AIDS (2003)
TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen
SUC Sankatsing et al.
AIDS (2003)
Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences
MA Jensen et al.
JOURNAL OF VIROLOGY (2003)
Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions
KJ Metzner et al.
JOURNAL OF INFECTIOUS DISEASES (2003)
Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus
J Lawrence et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Quality control trial for human immunodeficiency virus type 1 drug resistance testing using clinical samples reveals problems with detecting minority species and interpretation of test results
K Korn et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2003)
Geno2pheno:: estimating phenotypic drug resistance from HIV-1 genotypes
N Beerenwinkel et al.
NUCLEIC ACIDS RESEARCH (2003)
Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (Subtype E) infection differ from subtype B infection
K Ariyoshi et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2003)
Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1:: 2003 recommendations of an international AIDS Society-USA panel
MS Hirsch et al.
CLINICAL INFECTIOUS DISEASES (2003)
HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms
J Ravela et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2003)
Heterogeneous clearance rates of long-lived lymphocytes infected with HIV:: Intrinsic stability predicts lifelong persistence
MC Strain et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Accuracy of the TRUGENE HIV-1 genotyping kit
RM Grant et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2003)
Real versus virtual phenotype to guide treatment in heavily pretreated patients:: 48-week follow-up of the Genotipo-fenotipo di Resistenza (GenPheRex) trial
F Mazzotta et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2003)
A new perspective on V3 phenotype prediction
S Pillai et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2003)
Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients
AGV Marcelin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors
B Brenner et al.
AIDS (2003)
Quality assessment program for genotypic antiretroviral testing improves detection of drug resistance mutations
DC Sayer et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2003)
Antiretroviral-drug resistance among patients recently infected with HIV
SJ Little et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites
A Fehér et al.
EUROPEAN JOURNAL OF BIOCHEMISTRY (2002)
Time trends in primary HIV-1 drug resistance among recently infected persons
RM Grant et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop
NG Hoffman et al.
JOURNAL OF VIROLOGY (2002)
Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure:: a randomized trial
JL Meynard et al.
AIDS (2002)
Clinical utility of HIV-1 genotyping and expert advice:: the Havana trial
C Tural et al.
AIDS (2002)
Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine
V Picard et al.
JOURNAL OF INFECTIOUS DISEASES (2001)
Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks
W Resch et al.
VIROLOGY (2001)
Resistance-associated mutations in the human immunodeficiency virus type 1 subtype C protease gene from treated and untreated patients in the United Kingdom
PA Cane et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2001)
Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy
AJ Hance et al.
JOURNAL OF VIROLOGY (2001)
Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy
L Bacheler et al.
JOURNAL OF VIROLOGY (2001)
Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs
GR Kaufmann et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2001)
Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1
G Bleiber et al.
JOURNAL OF VIROLOGY (2001)
Use of genotypic resistance testing to guide HIV therapy: Clinical impact and cost-effectiveness
MC Weinstein et al.
ANNALS OF INTERNAL MEDICINE (2001)
Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.
SG Deeks et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir
HCF Cote et al.
JOURNAL OF VIROLOGY (2001)
Resistance to antiretroviral drugs in patients with primary HIV-1 infection
B Brenner et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2000)
Polymorphism of HIV type 1 Gag p7/p1 and p1/p6 cleavage sites: Clinical significance and implications for resistance to protease inhibitors
F Bally et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2000)
Simple algorithm derived from a geno-/phenotypic database to predict HIV-1 protease inhibitor resistance
B Schmidt et al.
AIDS (2000)
HIV type 1 protease cleavage site mutations and viral fitness: Implications for drug susceptibility phenotyping assays
LH Robinson et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2000)
Antiretroviral drug resistance testing in adult HIV-1 infection -: Recommendations of an International AIDS Society-USA panel
MS Hirsch et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1
CJ Petropoulos et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
Share Paper
